23.09.2016 09:43
AC Immune SA, a Swiss-based, biopharmaceutical company focused on neurodegenerative diseases, today announced that its common shares will open for trading on the NASDAQ Stock Market. CEO Prof. Andrea Pfeifer will be joined by members of AC Immune's senior team and guests at the First Trade Ceremony at NASDAQ’s headquarters in New York.